KAMADA » MEDIA » NEWS

NEWS


Kamada Reports Financial Results for Third Quarter and First Nine Months of 2018

Press Release / Nov. 12, 2018

Kamadad announced today financial results for the three and nine months ended September 30, 2018.

Kamada Announces Appointment of Life Sciences Industry Executive Eitan Kyiet as Vice President of Business Development

Press Release / Oct. 24, 2018

Kamada announced today the appointment of Eitan Kyiet as Vice President of Business Development. Mr. Kyiet has over 20 years of experience in business development, strategic operations and corporate law, with a significant portion of his career spent in the life sciences industry. He will lead Kamada's business development and strategic commercial activities, with a focus on advancing market opportunities for the Company's products. Mr. Kyiet will report directly to Amir London, Kamada’s Chief Executive Officer.

Kamada announced the extension of an ongoing investigator initiated, proof-of-concept study evaluating the potential benefit of the Company’s liquid Alpha-1 Antitrypsin (AAT) on liver preservation and transplant rejection prevention.

Press Release / Sep. 5, 2018

Kamada Announces Extension of Collaboration with Massachusetts General Hospital for a Proof-of-Concept Study Evaluating the Potential Benefit of Liquid Alpha-1 Antitrypsin on Liver Preservation Prior to Transplantation.

Kamada Provides Updated Full-Year 2018 Revenue Guidance

Press Release / Aug. 29, 2018

As result of the recent labor strike part of 2018 shipments are likely to be delayed to early 2019 Subsequent update and full-year 2019 revenue guidance to be provided later this year.

Kamada Announces the End of the Labor Strike in the Company’s Manufacturing Facility; All Employees Returned to Work

Press Release / Aug. 15, 2018

Kamada announced that on August 15, 2018, the Company, the Employees’ Committee of Kamada’s Beit Kama production facility in Israel (the “Employee’s Committee”), the Histadrut - General Federation of Labor in Israel (the “Histadrut”), and a Mediator appointed by the parties (the “Mediator”), signed a binding Memorandum of Understanding (the “Binding MoU”) that terminates the previously disclosed labor strike.

Kamada Receives Positive Scientific Advice from European Medicines Agency on a New Phase 3 Study Design for Inhaled AAT

Press Release / Jul. 10, 2018

Kamada announced that it has received positive scientific advice from the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) related to the development plan for its proposed pivotal Phase 3 study for its proprietary Inhaled Alpha-1 Antitrypsin therapy (Inhaled AAT) for the treatment of alpha-1 antitrypsin deficiency (AATD).

Results of Kamada’s Phase 2 Trial of Alpha-1 Antitrypsin in Newly Diagnosed Type-1 Diabetes Patients to be Presented at the Upcoming American Diabetes Association’s 78th Scientific Sessions

Press Release / Jun. 4, 2018

The results from the Company’s Phase 2 trial of Alpha-1 Antitrypsin (AAT) in newly diagnosed type-1 diabetes (T1D) will be presented in an oral session at the 78th Scientific Sessions of the American Diabetes Association (ADA).

Kamada Reports Financial Results for First Quarter of 2018

Press Release / May. 15, 2018

Kamada today announced financial results for the three months ended
March 31, 2018.

Kedrion Biopharma and Kamada Announce KEDRAB® (Rabies Immune Globulin [Human]) Now Shipping; Distribution Timed to Meet Spring/Summer Demand for Product

Press Release / May. 8, 2018

KEDRAB® [Rabies Immune Globulin (Human)] has been launched in the U.S. and initial shipments are now reaching healthcare practitioners across the country. Deliveries have been timed to meet growing demand for this product as the height of the 2018 spring/summer rabies season approaches.

Kamada Received Feedback from FDA on Proposed Phase 3 Protocol for Inhaled Alpha-1-Antitrypsin for Treatment of Alpha-1 Antitrypsin Deficiency Disease

Press Release / Apr. 24, 2018

Kamada announced that the company recently received feedback from the U.S. Food and Drug Administration (FDA) regarding the proposed pivotal Phase 3 protocol for its proprietary Inhaled Alpha-1 Antitrypsin (AAT) therapy (Inhaled AAT) for treatment of Alpha-1 Antitrypsin Deficiency (AATD).

out of 134 items.